ClinicalTrials.gg
RecruitingNCT07359261TAILOR-PEEPUpdated Apr 13, 2026

Transpulmonary Assessment for Individualized Lung Optimization in Obese Patients

A Phase 2 interventional study of Esophageal pressure-guided PEEP titration and Standard care PEEP management in Respiratory Failure, sponsored by University of Alberta. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by University of Alberta · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 94 studies in Respiratory Insufficiency with a site in Canada — 24 open to participants now, 29 under way, 1 of them phase 3. Respiratory Insufficiency · Canada.

Planned enrollment
34th of 66
30 · median 31
Started
2026
with 1 other
Phase 2
4 of 94
3 open now
Primary completion
2026-12
later than 17 of 28 live
Registered
93rd of 94
by date

Among the 94 studies in Respiratory Insufficiency with a site in Canada, this one is the 34th largest by planned enrollment of the 66 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 2, reaches primary completion later than 17 of the 28 other live ones, and was the 93rd registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

24 of the 94 studies in Respiratory Insufficiency with a site in Canada are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Respiratory Insufficiency with a site in Canada, or all of them as a file.
02

Study summary

This protocol describes a randomized controlled feasibility vanguard study designed to investigate the implementation and effects of esophageal pressure-guided positive end-expiratory pressure (PEEP) titration in patients with high body mass index (BMI) mechanically ventilated patients at the Edmonton Zone. The study will enroll 30 patients with body mass index (BMI) >=30 kg/m2 who require invasive mechanical ventilation, randomizing them in a 1:1 ratio to receive either esophageal pressure-guided PEEP titration or standard care management. The primary objective focuses on establishing the feasibility of conducting a larger definitive trial, while secondary objectives examine differences in applied PEEP levels, respiratory mechanics, and clinical outcomes between groups. The intervention protocol targets end-expiratory transpulmonary pressure of 0-2 cmH2O.

03

Conditions studied

  • Respiratory Failure

Keywords

  • PEEP
  • obesity
  • mechanical ventilation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • ≥30 kg/m²
  • Intubated and receiving passive mechanical ventilation
  • Within 24 hours of intubation
  • Anticipated need for mechanical ventilation for at least 48 hours

Exclusion criteria

Exclusion Criteria:

  • Known or suspected esophageal varices
  • Esophageal surgery within 3 months
  • Known esophageal stricture or perforation
  • Active upper gastrointestinal bleeding
  • Severe coagulopathy ( >3.0 or count \<30,000/μL)
  • Known or suspected intracranial hypertension without intracranial pressure monitoring device demonstrating controlled intracranial pressure (\<20 mmHg)
  • Severe hemodynamic instability at treating physician discretion
  • Known pregnancy
  • Moribund state with expected survival \<48 hours
  • Receiving extracorporeal membrane oxygenation (ECMO)
  • Open abdomen post-operatively
  • Previous enrollment in this study
  • Any other to esophageal balloon placement as determined by clinical team
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Esophageal-balloon guided

    Esophageal balloon catheter placed within 4 hours of randomization. PEEP titrated to achieve end-expiratory transpulmonary pressure of 0-2 cmH2O (up to 8 cmH2O for P/F ratio \<200). PEEP adjusted in 2 cmH2O increments with 5-minute stabilization periods. Safety limits: transpulmonary driving pressure \<15 cmH2O, end-inspiratory transpulmonary pressure \<20 cmH2O. Reassessment twice daily (approximately 0800 and 2200). Catheter removed prior to extubation or at 28 days, whichever occurs first.

    Procedure: Esophageal pressure-guided PEEP titration

  • Active comparator
    Standard of Care

    PEEP management according to current standard practice. For patients meeting ARDS criteria, PEEP titrated using the ARDSNet PEEP/FiO2 table. For non-ARDS patients, PEEP titrated per local practice to optimize oxygenation while monitoring hemodynamic tolerance and respiratory mechanics. No esophageal pressure monitoring.

    Other: Standard care PEEP management

Interventions

  • ProcedureEsophageal pressure-guided PEEP titration

    PEEP titration guided by transpulmonary pressure measurements using esophageal manometry. Esophageal balloon catheter inserted within 4 hours of randomization, positioned at 35-40 cm depth with position verified by cardiac oscillations and occlusion test. PEEP titrated in 2 cmH2O increments targeting end-expiratory transpulmonary pressure 0-2 cmH2O, with option to target up to 8 cmH2O for severe hypoxemia (P/F \<200). Safety limits enforced: transpulmonary driving pressure \<15 cmH2O, end-inspiratory transpulmonary pressure \<20 cmH2O. Measurements performed twice daily. Catheter removed at extubation or day 28.

    Also known as: Transpulmonary pressure-guided PEEP titration, Pes-guided PEEP management

  • OtherStandard care PEEP management

    PEEP management per institutional standard practice without esophageal pressure monitoring. For patients meeting ARDS criteria, PEEP titrated using ARDSNet low PEEP/FiO2 table. For non-ARDS patients, PEEP titrated to optimize oxygenation while monitoring hemodynamic tolerance and respiratory mechanics per treating clinician judgment.

06

What researchers measure

Primary outcomes

  1. Feasibility of conducting a definitive trial (composite)

    Composite feasibility assessment including: (1) Recruitment rate (patients enrolled per month, target 1-1.5/month); (2) Successful esophageal catheter placement rate in intervention arm; (3) Protocol adherence (percentage of scheduled transpulmonary pressure measurements completed, compliance with PEEP titration algorithm); (4) Data completeness for average PEEP over 7 days.

    Time frame: 14 months

Secondary outcomes

  1. Average PEEP

    Key secondary endpoint. Mean positive end-expiratory pressure during mechanical ventilation

    Time frame: 7 days

  2. Driving Pressure

    Difference in driving pressure between groups

    Time frame: 7 days

  3. Partial oxygen pressure over inspired oxygen fraction ratio

    P/F ratio

    Time frame: 7 days

  4. Days alive and free of mechanical ventilation

    Days alive and free of mechanical ventilation

    Time frame: Up to hospital discharge assessed up to 30 days

  5. Days alive and outside the intensive care unit

    Days alive and outside the intensive care unit

    Time frame: Up to hospital discharge assessed up to 30 days

  6. Hospital Mortality

    Hospital Mortality

    Time frame: Up to hospital discharge assessed up to 30 days

  7. Hemodynamics Instability

    Hemodynamics Instability during PEEP Titration defined as a new start of vasopressors at any dose or an increase in vasopressor dose by 20%

    Time frame: Up to 7 days

Other outcomes

  1. Catheter-related complications

    Occurrence of esophageal catheter complications (perforation, bleeding)

    Time frame: 7 days

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: After publication

Access criteria: Anonymized data may be shared after discussion with study steering committee, approval from ethics from University of Alberta, and establishment of data sharing agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.

Of 30 phase 2 interventional studies under Respiratory Insufficiency, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Jan 22, 2026
StartActual
Feb 5, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 1, 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07359261
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Feb 5, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

Fernando G Zampieri, MD
Contact
fzampier@ualberta.ca
780.492.9951
Caylin Chadwick, MSc
Contact
Caylin.Chadwick@albertahealthservices.ca
780.492.9951

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion